Blood test may unlock secrets of lung cancer drug resistance
NCT ID NCT04087473
First seen May 16, 2026 · Last updated Jun 22, 2026 · Updated 8 times
Summary
This study looked at blood samples from 50 people with a specific type of lung cancer (ALK-positive) that had stopped responding to targeted drugs. The goal was to find genetic changes in the cancer that cause resistance. By understanding these changes, doctors hope to match patients with the most effective next treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Asan Medical Centre
Seoul, 05505, South Korea
-
National Cancer Center Singapore
Singapore, 169690, Singapore
-
Seoul National University Hospital
Seoul, South Korea
-
The Chinese University of Hong Kong
Hong Kong, Hong Kong
-
University Malaya Medical Centre
Kuala Lumpur, Malaysia
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
What this could lead to
If successful, this could help doctors choose the right ALK inhibitor based on a patient's specific resistance mutation, potentially improving treatment outcomes.
What could go wrong
This is a small, completed observational study (50 participants) that only analyzed blood samples. It does not test a new treatment, so any benefits are indirect and uncertain.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.